{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:48:47Z","timestamp":1792014527244,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009399","name":"Peking University Third Hospital","doi-asserted-by":"publisher","award":["the Peking University Third Hospital Clinical Cohort Construction Program BYSYDL2023004"],"award-info":[{"award-number":["the Peking University Third Hospital Clinical Cohort Construction Program BYSYDL2023004"]}],"id":[{"id":"10.13039\/501100009399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009399","name":"Peking University Third Hospital","doi-asserted-by":"publisher","award":["Key Clinical Projects of Peking University Third Hospital No.BYSY2022051"],"award-info":[{"award-number":["Key Clinical Projects of Peking University Third Hospital No.BYSY2022051"]}],"id":[{"id":"10.13039\/501100009399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), exerts pleiotropic effects beyond erythropoiesis, including modulation of inflammation and immune responses. Preliminary studies suggest Roxadustat may modulate inflammation to reduce peritoneal dialysis-associated peritonitis (PDAP) risk, but this requires further proof.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients treated with Roxadustat or recombinant human erythropoietin (rhuEPO) at least three months from September 2014 and September 2024 were respectively enrolled. 1:1 propensity score matching (PSM) was performed based on age, sex, albumin, hemoglobin, lipid profiles, and initial urine volume. The primary outcome was PDAP incidence rate, expressed as episodes per person-year. Incidence rate ratios (IRRs) were estimated using Poisson regression models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 296 eligible patients, PSM yielded 136 well-balanced individuals (68 per group). Over 225.85 patient-years of follow-up, 41 peritonitis episodes were recorded. The Roxadustat group exhibited a significantly lower PDAP incidence rate than the rhuEPO group (0.131 vs. 0.212 episodes per patient-year). Multivariable Poisson regression, adjusted for age, potassium, and albumin, confirmed that Roxadustat was associated with lower PDAP risk (adjusted IRR 0.494, 95% CI 0.252\u20130.970;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.041). The trend persisted after multivariate adjustment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Roxadustat was associated with a reduced incidence of PDAP compared to rhuEPO, suggesting that HIF stabilization may offer protective benefits beyond anemia correction. Prospective validation is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10157-026-02926-6","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T08:08:59Z","timestamp":1786349339000},"page":"1619-1627","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Roxadustat and incidence of peritoneal dialysis-associated peritonitis: a propensity score\u2013matched cohort study"],"prefix":"10.1007","volume":"30","author":[{"given":"Ya-Hui","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2263-2979","authenticated-orcid":false,"given":"Wen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"issue":"10","key":"2926_CR1","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.ekir.2023.07.012","volume":"8","author":"I Teitelbaum","year":"2023","unstructured":"Teitelbaum I, Finkelstein FO. Why are we not getting more patients onto peritoneal dialysis? Observations from the United States with global implications. Kidney Int Rep. 2023;8(10):1917\u201323. https:\/\/doi.org\/10.1016\/j.ekir.2023.07.012.","journal-title":"Kidney Int Rep"},{"issue":"4","key":"2926_CR2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.xkme.2020.04.010","volume":"2","author":"M Al Sahlawi","year":"2020","unstructured":"Al Sahlawi M, Bargman JM, Perl J. Peritoneal dialysis-associated peritonitis: suggestions for management and mistakes to avoid. Kidney Med. 2020;2(4):467\u201375. https:\/\/doi.org\/10.1016\/j.xkme.2020.04.010.","journal-title":"Kidney Med"},{"key":"2926_CR3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2147\/IJNRD.S123618","volume":"11","author":"WL Salzer","year":"2018","unstructured":"Salzer WL. Peritoneal dialysis-related peritonitis: challenges and solutions. Int J Nephrol Renovasc Dis. 2018;11:173\u201386. https:\/\/doi.org\/10.2147\/IJNRD.S123618.","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"2suppl","key":"2926_CR4","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1177\/089686080902902s40","volume":"29","author":"R Kazancioglu","year":"2009","unstructured":"Kazancioglu R. Peritoneal defense mechanisms\u2014the effects of new peritoneal dialysis solutions. Perit Dialysis Int J Int Soc Perit Dialysis. 2009;29(2suppl):198\u2013201. https:\/\/doi.org\/10.1177\/089686080902902s40.","journal-title":"Perit Dialysis Int J Int Soc Perit Dialysis"},{"issue":"6","key":"2926_CR5","doi-asserted-by":"publisher","first-page":"100645","DOI":"10.1016\/j.xkme.2023.100645","volume":"5","author":"N Stepanova","year":"2023","unstructured":"Stepanova N. The gut-peritoneum axis in peritoneal dialysis and peritoneal fibrosis. Kidney Med. 2023;5(6):100645. https:\/\/doi.org\/10.1016\/j.xkme.2023.100645.","journal-title":"Kidney Med"},{"issue":"22","key":"2926_CR6","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.21037\/atm-22-5050","volume":"10","author":"W Zhang","year":"2022","unstructured":"Zhang W, Tan Y, Ai J, Luo F, Su X, Wu Q, et al. Comparison of risk of peritoneal dialysis-associated peritonitis between roxadustat and recombinant human erythropoietin in peritoneal dialysis patients: a retrospective comparative cohort study. Ann Transl Med. 2022;10(22):1212. https:\/\/doi.org\/10.21037\/atm-22-5050.","journal-title":"Ann Transl Med"},{"issue":"11","key":"2926_CR7","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","volume":"381","author":"N Chen","year":"2019","unstructured":"Chen N, Hao C, Liu B-C, Lin H, Wang C, Xing C, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med. 2019;381(11):1011\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1901713.","journal-title":"N Engl J Med"},{"issue":"1","key":"2926_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.kisu.2020.12.002","volume":"11","author":"VH Haase","year":"2021","unstructured":"Haase VH. Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease. Kidney Int Suppl (2011). 2021;11(1):8\u201325. https:\/\/doi.org\/10.1016\/j.kisu.2020.12.002.","journal-title":"Kidney Int Suppl (2011)"},{"issue":"3","key":"2926_CR9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jcmgh.2017.02.004","volume":"3","author":"MC Manresa","year":"2017","unstructured":"Manresa MC, Taylor CT. Hypoxia Inducible Factor (HIF) hydroxylases as regulators of intestinal epithelial barrier function. Cell Mol Gastroenterol Hepatol. 2017;3(3):303\u201315. https:\/\/doi.org\/10.1016\/j.jcmgh.2017.02.004.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"2","key":"2926_CR10","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40121-014-0030-1","volume":"3","author":"T Bhandari","year":"2014","unstructured":"Bhandari T, Nizet V. Hypoxia-Inducible Factor (HIF) as a pharmacological target for prevention and treatment of infectious diseases. Infect Dis Ther. 2014;3(2):159\u201374. https:\/\/doi.org\/10.1007\/s40121-014-0030-1.","journal-title":"Infect Dis Ther"},{"issue":"4","key":"2926_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/25785826.2021.1910187","volume":"44","author":"AA Kiani","year":"2021","unstructured":"Kiani AA, Elyasi H, Ghoreyshi S, Nouri N, Safarzadeh A, Nafari A. Study on hypoxia-inducible factor and its roles in immune system. Immunol Med. 2021;44(4):223\u201336. https:\/\/doi.org\/10.1080\/25785826.2021.1910187.","journal-title":"Immunol Med"},{"key":"2926_CR12","doi-asserted-by":"publisher","first-page":"149387","DOI":"10.1016\/j.bbrc.2023.149387","volume":"693","author":"L Wang","year":"2024","unstructured":"Wang L, Fan J, Yang T, Shen J, Wang L, Ge W. Investigating the therapeutic effects and mechanisms of roxadustat on peritoneal fibrosis based on the TGF-beta\/Smad pathway. Biochem Biophys Res Commun. 2024;693:149387. https:\/\/doi.org\/10.1016\/j.bbrc.2023.149387.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"2926_CR13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s40001-023-01179-3","volume":"28","author":"XN Zhao","year":"2023","unstructured":"Zhao XN, Liu SX, Wang ZZ, Zhang S, You LL. Roxadustat alleviates the inflammatory status in patients receiving maintenance hemodialysis with erythropoiesis-stimulating agent resistance by increasing the short-chain fatty acids producing gut bacteria. Eur J Med Res. 2023;28(1):230. https:\/\/doi.org\/10.1186\/s40001-023-01179-3.","journal-title":"Eur J Med Res"},{"issue":"5","key":"2926_CR14","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1681\/ASN.V75745","volume":"7","author":"RW van Olden","year":"1996","unstructured":"van Olden RW, Krediet RT, Struijk DG, Arisz L. Measurement of residual renal function in patients treated with continuous ambulatory peritoneal dialysis. J Am Soc Nephrol. 1996;7(5):745\u201350. https:\/\/doi.org\/10.1681\/ASN.V75745.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2926_CR15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1177\/089686089301300303","volume":"13","author":"KD Nolph","year":"1993","unstructured":"Nolph KD, Moore HL, Prowant B, Meyer M, Twardowski ZJ, Khanna R, et al. Cross sectional assessment of weekly urea and creatinine clearances and indices of nutrition in continuous ambulatory peritoneal dialysis patients. Perit Dialysis International: J Int Soc Perit Dialysis. 1993;13(3):178\u201383. https:\/\/doi.org\/10.1177\/089686089301300303.","journal-title":"Perit Dialysis Int J Int Soc Perit Dialysis"},{"issue":"5","key":"2926_CR16","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1177\/089686089701700506","volume":"17","author":"AM Fernandez Rodriguez","year":"1997","unstructured":"Fernandez Rodriguez AM, Vega Diaz N, Palop Cubillo L, Baamonde Laborda E, Morales Umpierrez A, Perez Borges P, et al. Adequacy of dialysis in automated peritoneal dialysis: a clinical experience. Perit Dial Int. 1997;17(5):442\u20138.","journal-title":"Perit Dial Int"},{"issue":"2","key":"2926_CR17","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3747\/pdi.2010.00055","volume":"31","author":"W Tang","year":"2011","unstructured":"Tang W, Xue T, Lu XH, Luo YJ, Wang T. Factors contributing to formation of edema in volume overloaded continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 2011;31(2):160\u20137. https:\/\/doi.org\/10.3747\/pdi.2010.00055.","journal-title":"Perit Dial Int"},{"issue":"2","key":"2926_CR18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1177\/08968608221080586","volume":"42","author":"PK Li","year":"2022","unstructured":"Li PK, Chow KM, Cho Y, Fan S, Figueiredo AE, Harris T, et al. ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Perit Dial Int. 2022;42(2):110\u201353. https:\/\/doi.org\/10.1177\/08968608221080586.","journal-title":"Perit Dial Int"},{"key":"2926_CR19","doi-asserted-by":"publisher","first-page":"967532","DOI":"10.3389\/fphar.2022.967532","volume":"13","author":"S Chong","year":"2022","unstructured":"Chong S, Xie Q, Ma T, Xiang Q, Zhou Y, Cui Y. Risk of infection in roxadustat treatment for anemia in patients with chronic kidney disease: a systematic review with meta-analysis and trial sequential analysis. Front Pharmacol. 2022;13:967532. https:\/\/doi.org\/10.3389\/fphar.2022.967532.","journal-title":"Front Pharmacol"},{"issue":"4","key":"2926_CR20","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1007\/s12325-023-02433-0","volume":"40","author":"J Barratt","year":"2023","unstructured":"Barratt J, Dellanna F, Portoles J, Choukroun G, De Nicola L, Young J, et al. Safety of roxadustat versus erythropoiesis-stimulating agents in patients with anemia of non-dialysis-dependent or incident-to-dialysis chronic kidney disease: pooled analysis of four phase 3 studies. Adv Ther. 2023;40(4):1546\u201359. https:\/\/doi.org\/10.1007\/s12325-023-02433-0.","journal-title":"Adv Ther"},{"issue":"2","key":"2926_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/1744-9987.12888","volume":"24","author":"T Akizawa","year":"2019","unstructured":"Akizawa T, Otsuka T, Reusch M, Ueno M. Intermittent oral dosing of roxadustat in peritoneal dialysis chronic kidney disease patients with anemia: a randomized, phase 3, multicenter, open-label study. Therapeutic Apheresis Dialysis. 2019;24(2):115\u201325. https:\/\/doi.org\/10.1111\/1744-9987.12888.","journal-title":"Therapeutic Apheresis Dialysis"},{"key":"2926_CR22","doi-asserted-by":"publisher","unstructured":"Fliser D, Bhandari S, Ortiz A, Santos V, Khalife N, Jiletcovici A, et al. Roxadustat efficacy and safety in patients receiving peritoneal dialysis: pooled analysis of four phase 3 studies. J Clin Med. 2024;13(22). https:\/\/doi.org\/10.3390\/jcm13226729.","DOI":"10.3390\/jcm13226729"},{"issue":"2","key":"2926_CR23","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1093\/ckj\/sfv142","volume":"9","author":"L Del Vecchio","year":"2016","unstructured":"Del Vecchio L, Longhi S, Locatelli F. Safety concerns about intravenous iron therapy in patients with chronic kidney disease. Clin Kidney J. 2016;9(2):260\u20137. https:\/\/doi.org\/10.1093\/ckj\/sfv142.","journal-title":"Clin Kidney J"},{"issue":"9","key":"2926_CR24","doi-asserted-by":"publisher","first-page":"e2255","DOI":"10.1002\/hsr2.2255","volume":"7","author":"AJ Nashwan","year":"2024","unstructured":"Nashwan AJ, Abuawwad MT, Jaradat JH, Ibraheem A, Yassin MA, Taha MJJ. Prevalence of iron overload in patients with chronic kidney disease on peritoneal dialysis: a scoping review. Health Sci Rep. 2024;7(9):e2255. https:\/\/doi.org\/10.1002\/hsr2.2255.","journal-title":"Health Sci Rep"},{"key":"2926_CR25","doi-asserted-by":"publisher","unstructured":"Ganz T, Locatelli F, Arici M, Akizawa T, Reusch M. Iron Parameters in Patients Treated with Roxadustat for Anemia of Chronic Kidney Disease. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12134217.","DOI":"10.3390\/jcm12134217"},{"issue":"10","key":"2926_CR26","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/aor.14001","volume":"45","author":"G Innico","year":"2021","unstructured":"Innico G, Gobbi L, Bertoldi G, Rigato M, Basso A, Bonfante L, et al. Oxidative stress, inflammation, and peritoneal dialysis: a molecular biology approach. Artif Organs. 2021;45(10):1202\u20137. https:\/\/doi.org\/10.1111\/aor.14001.","journal-title":"Artif Organs"},{"key":"2926_CR27","doi-asserted-by":"publisher","first-page":"912595","DOI":"10.1155\/2012\/912595","volume":"2012","author":"G Baroni","year":"2012","unstructured":"Baroni G, Schuinski A, de Moraes TP, Meyer F, Pecoits-Filho R. Inflammation and the peritoneal membrane: causes and impact on structure and function during peritoneal dialysis. Mediators Inflamm. 2012;2012:912595. https:\/\/doi.org\/10.1155\/2012\/912595.","journal-title":"Mediators Inflamm"},{"key":"2926_CR28","doi-asserted-by":"publisher","unstructured":"Roumeliotis S, Dounousi E, Salmas M, Eleftheriadis T, Liakopoulos V. Unfavorable Effects of Peritoneal Dialysis Solutions on the Peritoneal Membrane: The Role of Oxidative Stress. Biomolecules. 2020;10(5). https:\/\/doi.org\/10.3390\/biom10050768.","DOI":"10.3390\/biom10050768"},{"key":"2926_CR29","doi-asserted-by":"publisher","unstructured":"Choukroun G, Strutz F, Harkavyi A, Santos V, Jiletcovici A, Del Vecchio L. Efficacy and Safety of Roxadustat in Patients with CKD: Pooled Analysis by Baseline Inflammation Status. J Clin Med. 2025;14(2). https:\/\/doi.org\/10.3390\/jcm14020303.","DOI":"10.3390\/jcm14020303"},{"key":"2926_CR30","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3389\/fphar.2020.01191","volume":"11","author":"G Long","year":"2020","unstructured":"Long G, Chen H, Wu M, Li Y, Gao L, Huang S, et al. Antianemia drug roxadustat (FG-4592) protects against doxorubicin-induced cardiotoxicity by targeting antiapoptotic and antioxidative pathways. Front Pharmacol. 2020;11:1191. https:\/\/doi.org\/10.3389\/fphar.2020.01191.","journal-title":"Front Pharmacol"},{"issue":"Supplement3","key":"2926_CR31","doi-asserted-by":"publisher","first-page":"S233","DOI":"10.1513\/AnnalsATS.201608-610MG","volume":"14","author":"LE Glover","year":"2017","unstructured":"Glover LE, Colgan SP. Epithelial barrier regulation by hypoxia-inducible factor. Ann Am Thorac Soc. 2017;14(Supplement3):S233\u20136. https:\/\/doi.org\/10.1513\/AnnalsATS.201608-610MG.","journal-title":"Ann Am Thorac Soc"},{"issue":"11","key":"2926_CR32","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1681\/asn.2016010112","volume":"27","author":"R Mehrotra","year":"2016","unstructured":"Mehrotra R, Devuyst O, Davies SJ, Johnson DW. The current state of peritoneal dialysis. J Am Soc Nephrol. 2016;27(11):3238\u201352. https:\/\/doi.org\/10.1681\/asn.2016010112.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2926_CR33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/0896860821996096","volume":"42","author":"MR Marshall","year":"2022","unstructured":"Marshall MR. A systematic review of peritoneal dialysis-related peritonitis rates over time from national or regional population-based registries and databases. Perit Dial Int. 2022;42(1):39\u201347. https:\/\/doi.org\/10.1177\/0896860821996096.","journal-title":"Perit Dial Int"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02926-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-026-02926-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02926-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:09:41Z","timestamp":1792012181000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-026-02926-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["2926"],"URL":"https:\/\/doi.org\/10.1007\/s10157-026-02926-6","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No potential conflict of interest was reported by the authors.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study followed the Declaration of Helsinki and was approved by the Peking University Ethics Committee (No. 096\u2009\u2212\u200903). The IRB waived informed consent given the retrospective design and use of anonymized data.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No animals were involved in this research so a statement on their welfare does not apply.","order":3,"name":"Ethics","label":"Human and animal rights","group":{"name":"EthicsHeading","label":"Declarations"}}]}}